Ketorolac is a potent nonsteroidal anti-inflammatory drug (NSAID) and the active ingredient used in the brand medication Toradol. It is designed for short-term management of moderate to severe acute pain, offering strong, opioid-sparing analgesia through inhibition of prostaglandin synthesis. Ketorolac is widely used in postoperative care, emergency medicine, and acute injury scenarios where rapid, non-opioid pain relief is required.
The molecule is available in several clinically important forms, including oral tablets, injectable IM/IV formulations (see Toradol injection), and ophthalmic drops used under separate indications. While Toradol refers to the branded product, ketorolac represents the underlying pharmacologically active compound. For a broader clinical context, see the Toradol overview page.
Ketorolac is a potent nonsteroidal anti-inflammatory drug (NSAID) used primarily as a short-term analgesic for moderate to severe acute pain. It belongs to the same broad class as ibuprofen and naproxen but is positioned closer to opioid-level analgesia in terms of strength. Unlike opioids, ketorolac does not act on opioid receptors and does not cause opioid-like dependence or respiratory depression. Its clinical value lies in providing strong, non-opioid pain relief in postoperative care, emergency settings, and acute injury scenarios where rapid, robust analgesia is required but long-term therapy is not intended.
Ketorolac works by inhibiting cyclooxygenase (COX) enzymes, which are responsible for the synthesis of prostaglandins—lipid mediators that promote pain, inflammation, and fever. By reducing prostaglandin production, ketorolac lowers peripheral sensitization and decreases the intensity of pain signals. This mechanism explains why it is stronger than many standard NSAIDs: its COX inhibition is more pronounced, resulting in a more powerful analgesic effect. However, prostaglandins also protect the gastrointestinal tract, kidneys, and platelet function. Prolonged suppression increases the risk of GI bleeding, renal impairment, and bleeding tendencies. For this reason, ketorolac is restricted to short-term use, typically over a limited number of days, and is not used as a chronic or routine pain reliever despite its high efficacy.
Ketorolac is available in several formulations designed to cover different phases and settings of acute pain management. The most widely used forms are oral tablets, injectable solutions, ophthalmic drops, and, in some regions, a nasal spray. Each formulation has a specific clinical role, from rapid parenteral analgesia in hospitals to short-term continuation therapy in outpatient care.
Oral tablets (10 mg) are commonly used after initial parenteral treatment, providing short-term continuation of analgesia once the patient can take medications by mouth. More details are available on the ketorolac 10 mg page.
Injectable ketorolac (30 mg and 60 mg) is used intramuscularly or intravenously in hospitals, surgical centers, and emergency departments. The 30 mg IM/IV dose is frequently used for acute postoperative pain, while 60 mg IM may be reserved for severe acute pain under close supervision. These are covered on the ketorolac 30 mg injection page.
Ophthalmic ketorolac (Acular) is formulated as 0.5% eye drops for postoperative ocular pain and inflammation. Although it contains the same active ingredient, it serves a distinct therapeutic purpose and is discussed in detail on the Acular ketorolac page.
Nasal spray ketorolac offers a non-invasive route with relatively rapid absorption and may be used in select acute pain scenarios where oral administration is not feasible and injections are undesirable.
Ketorolac is primarily indicated for short-term treatment of moderate to severe acute pain. It is widely used in postoperative settings to reduce pain after surgical procedures, often as part of a multimodal analgesia strategy. Ketorolac is also used for acute musculoskeletal injuries, severe back pain episodes, and trauma-related pain where strong, non-opioid analgesia is needed. Its role in these scenarios is similar to that of Toradol, and more clinical context can be found on the Toradol for Pain page.
Beyond standard postoperative and trauma-related use, ketorolac may be employed in several specific acute conditions. It is sometimes used for renal colic, where its anti-inflammatory and analgesic effects can help reduce pain intensity. In emergency settings, parenteral ketorolac may be used for severe migraine attacks, particularly when oral medications are ineffective or not tolerated; this is discussed further on the Toradol for Migraine page. Ophthalmic ketorolac (Acular) is indicated for postoperative eye pain and inflammation after ocular surgery. Across all these scenarios, ketorolac is reserved for short-term use, with careful attention to its gastrointestinal, renal, and bleeding risk profile.
Ketorolac dosing is designed to balance strong analgesic effects with a strict safety margin. Typical oral doses involve 10 mg tablets, while injectable formulations are commonly available as 30 mg and 60 mg solutions for IM or IV use. The choice of dose and route depends on the clinical setting, pain intensity, and patient factors, with parenteral administration often used first for rapid relief and oral therapy used briefly afterward.
A key principle of ketorolac therapy is short-term use. Prolonged exposure increases the risk of gastrointestinal bleeding, renal impairment, and bleeding tendencies. More detail on duration limits and rationale is provided on the Toradol short-term use page. Maximum treatment duration is generally brief, and cumulative daily doses are carefully controlled.
Injectable ketorolac can be given intramuscularly or intravenously, and the choice between IM and IV routes is influenced by onset requirements, clinical context, and institutional protocols. Differences between these routes and their practical implications are discussed on the Toradol IM vs IV page. Overall, ketorolac dosing strategies emphasize strong, fast-acting analgesia within a tightly limited time frame, rather than ongoing or chronic pain management.
The core difference between ketorolac and Toradol is naming: ketorolac is the active pharmaceutical ingredient, while Toradol is a brand name that contains ketorolac. In terms of pharmacologic effect, they are the same molecule and provide equivalent analgesic efficacy when used at comparable doses and in similar formulations. Many generic products simply use the name “ketorolac,” whereas branded products may be labeled as “Toradol” in specific markets.
Differences can arise in available forms, packaging, and regional approvals. Some regions may offer certain strengths or routes (such as specific injectable concentrations or nasal spray formulations) under the Toradol brand, while others provide them as generic ketorolac. In search behavior, users often look for both terms—“ketorolac” to understand the molecule and “Toradol” to explore branded products, clinical use, and purchasing options. From a clinical perspective, the underlying analgesic effect is driven by ketorolac itself, regardless of whether it is branded or generic.
Ketorolac is valued for its strong analgesic effect, rapid onset, and non‑opioid mechanism. It provides pain relief comparable to lower‑dose opioids without acting on opioid receptors, making it useful in postoperative care, emergency medicine, and acute injury scenarios. Its fast action and ability to reduce moderate to severe pain without sedation or dependence are key advantages that distinguish it from many standard NSAIDs.
However, ketorolac also has notable limitations. Because it strongly inhibits prostaglandin synthesis, prolonged use increases the risk of gastrointestinal irritation, ulceration, kidney stress, and bleeding tendencies. These risks are more pronounced in older adults, individuals with renal concerns, and those with a history of GI issues. Ketorolac is therefore restricted to short‑term therapy and is not used for chronic or mild pain. Age‑related considerations, cumulative exposure, and interactions with other NSAIDs further limit its use. Overall, ketorolac is highly effective when used briefly for acute pain but requires careful attention to safety boundaries.
Ketorolac, like other NSAIDs, may cause gastrointestinal discomfort such as stomach pain, nausea, indigestion, or heartburn. These effects occur because prostaglandins help protect the stomach lining, and their inhibition increases sensitivity to irritation. Some individuals may also experience dizziness, headache, or fluid retention. Temporary changes in kidney function can occur, especially in people who are dehydrated or have underlying renal concerns. Injection‑related effects may include localized pain, swelling, or mild bruising at the administration site. These common reactions are generally manageable but contribute to the recommendation that ketorolac be used only for short periods.
More serious risks include gastrointestinal bleeding, ulcer formation, and kidney injury, particularly when ketorolac is used beyond the recommended duration. Because prostaglandins support kidney perfusion and GI protection, prolonged inhibition increases the likelihood of complications. Ketorolac may also affect platelet function, leading to increased bleeding tendencies during or after surgical procedures. Rare cardiovascular effects, such as elevated blood pressure or thrombotic events, are considerations shared with other NSAIDs. These risks explain why ketorolac is reserved for short‑term use and why clinicians monitor duration and cumulative exposure carefully.
Ketorolac is not used in individuals with active gastrointestinal ulcers, recent GI bleeding, or a history of perforation, as its strong prostaglandin inhibition can worsen these conditions. It is also avoided in people with severe kidney impairment, since reduced renal blood flow may further compromise kidney function. Hypersensitivity to NSAIDs, including reactions such as asthma, hives, or anaphylactoid responses, is another major contraindication.
Age‑related restrictions apply as well. Older adults may be more susceptible to gastrointestinal and renal side effects, and dosing strategies often reflect this increased sensitivity. Ketorolac is intended strictly for short‑term use, and prolonged therapy is avoided to reduce the likelihood of serious complications.
Combining ketorolac with other NSAIDs is generally avoided because it increases the risk of gastrointestinal irritation, kidney stress, and bleeding. Alcohol consumption may further irritate the stomach lining and increase the likelihood of GI complications, which is why concurrent use is discouraged. Overall, ketorolac’s contraindications and limitations reflect its potency and the need to balance strong analgesia with careful safety considerations.
| Form | Dosage | Route | Pain Type / Situation |
|---|---|---|---|
| Tablets | 10 mg | Oral | Continuation of therapy after injections |
| Injection | 30 mg | IM/IV | Acute pain, hospital setting |
| Injection | 60 mg | IM | Severe acute pain, single-dose administration |
| Acular (ophthalmic) | 0.5% | Ophthalmic | Postoperative eye pain |
This table summarizes the primary ketorolac formulations and their typical clinical roles. Parenteral injections are used for rapid, high-intensity analgesia in postoperative or emergency settings, while oral tablets extend therapy for a short period once the patient is stable. Acular, the ophthalmic form, is used for postoperative ocular pain and inflammation. The structured overview helps clarify how each form fits into short-term acute pain management.
| Drug | Analgesic Strength | Onset | Risks | Typical Use |
|---|---|---|---|---|
| Ketorolac | High | Fast | Medium/High | Acute pain |
| Ibuprofen | Medium | Medium | Low | Mild/Moderate pain |
| Naproxen | Medium | Slow | Medium | Inflammatory conditions |
| Diclofenac | Medium | Fast | Medium | Joint and musculoskeletal pain |
This comparison highlights ketorolac’s position as one of the strongest NSAIDs available for short-term acute pain. Its rapid onset and high analgesic strength make it suitable for postoperative and emergency scenarios, while ibuprofen, naproxen, and diclofenac are more commonly used for routine or chronic pain management. The higher risk profile of ketorolac explains why its use is limited to brief treatment windows.
| Form | Onset | Duration |
|---|---|---|
| Injection | Fast | Moderate |
| Tablets | Moderate | Moderate |
| Acular (ophthalmic) | Fast | Short |
Different ketorolac formulations vary in onset and duration. Injections provide the fastest relief and are used for acute, high-intensity pain. Tablets offer a moderate onset suitable for short continuation therapy. Acular delivers rapid but short-lasting relief for postoperative ocular discomfort. This structure helps clarify how each form fits into short-term pain management.